Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | ![]() Retinal Disorders – Therapy Market SnapshotReportsWorldwide has announced the addition of a new report title Retinal Disorders – Therapy Market Snapshot to its growing collection of premium market research reports.
By: ReportsWorldwide The report of 142 pages, 40 tables and 35 figures covers the below topics in detail: • Treatment • Marketed Drugs –Profiles of Avastin, Eylea, Lucentis and Ozurdex • Drug Pipeline – Late stage product profiles of Zuprata, abicipar pegol, brolucizumab and squalamine For a Detailed description and table of contents of this Datamonitor Healthcare report please click here: www.reportsworldwide.com/ Below is a Snapshot of Retina Disorders therapy market : • New therapies will sustain market growth beyond expiries for first-generation anti-VEGF injections. • Anti-VEGFs lead treatment dynamics, although choice of specific therapy is widely variable between countries. • Common retinal disorders will contribute to over four million cases in 2016; this is expected to rise in the future. • Eylea has become the clinical gold standard and market-leading anti-VEGF therapy. • Brolucizumab's Phase III data position it as a direct competitor to the $5bn VEGF inhibitor Eylea. To Get Sample Copy of Report please visit @ www.reportsworldwide.com/ About ReportsWorldwide.com ReportsWorldwide.com is a leading provider of global market intelligence reports and services. With research reports from top publishers, consulting and advisory firms, ReportsWorldwide.com offers instant online access to a growing database of expert insights on global industries, companies, products, geographies and trends. End
|
|